Updated evidence for oral PCSK9 inhibitors: a drug-specific, GRADE-assessed systematic review and meta-analysis of phase 3 enlicitide trials
Frontiers in Pharmacology · 16.11.2026 · 17
DOI: 10.3389/fphar.2026.1904883 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.11.2026. Verfasst von Santenna Chenchula und 14 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging class of lipid-lowering therapies that may improve adherence and accessibility compared with injectable agents.
Methods
We systematically searched PubMed, Scopus, and Embase from inception to March 2026 for randomized controlled trials evaluating oral PCSK9 inhibitors (enlicitide, NNC0385-0434, AZD0780) in adults with hypercholesterolaemia. The primary outcome was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary outcomes included any adverse events, serious adverse events, and discontinuation due to adverse events. Pooled estimates were calculated using random-effects models. Heterogeneity was assessed with I2 statistics. Certainty of evidence was evaluated using the GRADE framework.
Results
Five trials comprising 4,065 participants were included. Oral PCSK9 inhibitors significantly reduced LDL-C compared with placebo (mean difference −58.37%, 95% CI –59.99 to −56.75; I2 = 0%). In drug-specific subgroup analysis, enlicitide (phase 3) showed a reduction of −58.57% (95% CI –60.30 to −56.84; I2 = 0%), while other agents (phase 2) showed a reduction of −56.88% (95% CI –63.13 to −50.64; I2 = 39.7%). There were no significant differences between treatment and placebo for any adverse events (RR 0.99, 95% CI 0.97–1.02), serious adverse events (RR 0.94, 95% CI 0.63–1.40), or discontinuation due to adverse events (RR 1.05, 95% CI 0.88–1.25). Certainty of evidence was high for LDL-C reduction, any adverse events, and discontinuation due to adverse events, and moderate for serious adverse events.
Discussion
Oral PCSK9 inhibitors provide substantial LDL-C reductions with a safety profile comparable to placebo. These agents represent a promising oral alternative to injectable PCSK9-targeted therapies, though long-term cardiovascular outcome trials are still needed.
Zitieren
APA
Chenchula, S., Ghanta, S. N., R, P., Amerneni, K. C., Uppugunduri, C. R. S., Gunasekaran, M., Padavala, A., Chebrolu, H. C., Arora, S., T, S. V., S, U. N. K., Saggurthi, P., Ghanta, M. K., Amerneni, L. S., & Chavan, M. (2026). Updated evidence for oral PCSK9 inhibitors: a drug-specific, GRADE-assessed systematic review and meta-analysis of phase 3 enlicitide trials. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1904883
Vancouver
Chenchula S, Ghanta SN, R P, Amerneni KC, Uppugunduri CRS, Gunasekaran M, et al. Updated evidence for oral PCSK9 inhibitors: a drug-specific, GRADE-assessed systematic review and meta-analysis of phase 3 enlicitide trials. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1904883
BibTeX
@article{Chenchula2026,
author = {Chenchula, Santenna and Ghanta, Sai Nikhila and R, Padmavathi and Amerneni, Krishna Chaitanya and Uppugunduri, Chakradhara Rao S and Gunasekaran, Mounika and Padavala, Ashrai and Chebrolu, Harshitha Chowdary and Arora, Sakshi and T, Sri Vasista and S, Uday Narendra Kumar and Saggurthi, Pavani and Ghanta, Mohan Krishna and Amerneni, Lakshmi Sahitya and Chavan, Madhavrao},
title = {Updated evidence for oral PCSK9 inhibitors: a drug-specific, GRADE-assessed systematic review and meta-analysis of phase 3 enlicitide trials},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1904883}
}
EUVIMED